



# Predictors of response to CDK4/6i retriial after prior CDK4/6i failure in ER+ metastatic breast cancer



Nicholas Mai<sup>1</sup>, Carlos H. dos Anjos<sup>2</sup>, Pedram Razavi<sup>1</sup>, Anton Safonov<sup>1</sup>, Sujata Patil<sup>3</sup>, Yuan Chen<sup>4</sup>, Joshua Z. Drago<sup>1</sup>, Shanu Modi<sup>1</sup>, Jacqueline F. Bromberg<sup>1</sup>, Chau T. Dang<sup>1</sup>, Dazhi Liu<sup>1</sup>, Larry Norton<sup>1</sup>, Mark Robson<sup>1</sup>, Sarat Chandarlapaty<sup>1</sup> & Komal Jhaveri<sup>1</sup> ✉

After disease progression on endocrine therapy (ET) plus a CDK4/6 inhibitor, there is no standardized sequence for subsequent treatment lines for estrogen receptor positive (ER+) metastatic breast cancer (MBC). CDK4/6i retriial as a treatment strategy is commonplace in modern clinical practice; however, the available prospective data investigating this strategy have had inconclusive results. To frame this data in a real-world context, we performed a retrospective analysis assessing the efficacy of CDK4/6is in 195 patients who had previous exposure to CDK4/6i in a prior treatment line at our institution. Among patients who had stopped a CDK4/6i due to toxicity, CDK4/6i retriial either immediately after with a different CDK4/6i or in a further treatment line with the same initial CDK4/6i was both safe and effective, with a median time to treatment failure (TTF) of 10.1 months (95%CI, 4.8–16.9). For patients whose disease progressed on a prior CDK4/6i, we demonstrated comparable median TTFs for patients rechallenged with the same CDK4/6i (4.3 months, 95%CI 3.2–5.5) and with a different CDK4/6i (4.7 months, 95%CI 3.7–6.0) when compared to the recent PACE, PALMIRA, and MAINTAIN trials. Exploratory genomic analysis suggested that the presence of mutations known to confer CDK4/6i resistance, such as *TP53* mutations, *CDK4* amplifications, and *RB1* or *FAT1* loss of function mutations may be molecular biomarkers predictive of CDK4/6i retriial failure.

Estrogen-receptor positive (ER+) HER2 negative breast cancer is the most common breast cancer subtype, accounting for almost 60–65% of all breast cancers<sup>1</sup>. ER+ breast cancer has the tendency for both locoregional and distant recurrence decades after initial diagnosis and treatment, with almost 20–30% of patients developing metastatic breast cancer (MBC) in this time<sup>2</sup>. First-line treatment for ER+ MBC is a combination of endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), where data from both the initial clinical trials and follow-up meta-analyses have shown significant improvements in both progression-free survival (PFS) and overall survival (OS) when compared to ET alone<sup>3–5</sup>. However, despite the significant improvements in outcomes in ER+ MBC with the addition of CDK4/6i, resistance to both ET and CDK4/6i occurs almost universally after enough time<sup>6,7</sup>.

After progression on ET + CDK4/6i, there are many treatment options available for patients, but each subsequent treatment line has

progressively diminishing efficacy and tolerability, while many are reliant upon specific molecular markers for treatment eligibility<sup>8</sup>. However, despite the variety of options, there is no standard, optimal treatment after first line ET + CDK4/6i. Similar to how anti-HER2 targeting therapies can be offered again to patients with HER2+ disease even after they progress through first-line trastuzumab + pertuzumab<sup>9</sup>, it is of similar interest whether patients may benefit with continuing ET + CDK4/6i after initial progression or returning to it in subsequent treatment lines. Especially with increasing evidence for and usage of CDK4/6i in the adjuvant setting, understanding the circumstances where retriial would be useful becomes even more relevant. A few prospective, randomized phase II clinical trials trying to answer this question already have preliminary, though conflicting results. Both the PACE and PALMIRA trials saw no improvements in PFS when comparing palbociclib + ET to ET alone in patients with ER+ MBC that had

<sup>1</sup>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. <sup>2</sup>Oncology Service, Department of Medicine, Hospital Sirio-Libanês, Sao Paulo, SP, Brazil. <sup>3</sup>Department of Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.

<sup>4</sup>Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

✉ e-mail: [jhaverik@mskcc.org](mailto:jhaverik@mskcc.org)

previously progressed on an aromatase inhibitor (AI) + a prior CDK4/6i (technically any CDK4/6i for PACE, palbociclib exclusively for PALMIRA)<sup>10,11</sup>. In contrast, the MAINTAIN trial, which compared ribociclib + ET to ET alone in patients previously exposed to any prior CDK4/6i therapy showed a significant PFS benefit for the ribociclib combination therapy arm<sup>12</sup>. For further context, in all trials, the overwhelming majority of patients' first CDK4/6i was palbociclib even for the trials that did not actively select for this (91% of patients in PACE<sup>13</sup> and 87% in MAINTAIN<sup>12</sup>), with PACE and PALMIRA designed primarily to address the clinical utility of retreating with palbociclib but switching ET after primary progression on palbociclib, while MAINTAIN addressed the utility of changing ET and CDK4/6i.

To further clarify the clinical utility of CDK4/6i retri al after progression on first-line ET + CDK4/6i therapy in ER+ MBC and to complement the prospective studies mentioned above, we performed a retrospective clinical and genomic analysis on patients treated at Memorial Sloan Kettering Cancer Center (MSK) with at least two documented treatment lines containing CDK4/6i. Our cohorts included patients retreated with the same CDK4/6i and patients treated with a different CDK4/6i. Here we report real-world efficacy and toxicity data of this CDK4/6i retri al treatment strategy coupled with a descriptive genomic analysis of the patients in our study.

## Results

### Patients characteristics

A total of 195 ER+/HER2- patients with MBC treated at MSK with at least 2 separate treatment regimens containing a CDK4/6i between May 2014 and December 2020 were identified. Median age for all patients identified was 60. Patients were divided into three cohorts based upon the criteria outlined in Fig. 1. Of the 195 total, 14 patients received three regimens containing a CDK4/6i and contributed to two different cohorts. Clinical characteristics for all patients in all cohorts are summarized in Table 1. Of note, all 195 patients were treated for metastatic disease by the time of first CDK4/6i exposure, and no patients were treated for adjuvant disease.

In Cohort 1 (*n* = 34), the group of patients that had to stop first-line CDK4/6i purely due to toxicity, the most common toxicities leading to discontinuation were neutropenia (32%), skin rash (17.5%), and joint pain (17%). At the time of CDK4/6i retri al, 7 patients (20.5%) again had to stop treatment due to toxicity, with 6 out of 7 patients stopping for the same toxicity that caused discontinuation of first line treatment. Of the 7 patients in this cohort that had to stop CDK4/6i retri al due to treatment toxicity, 6 patients still had to stop retri al therapy due to the same toxicity that prompted

discontinuation of their initial CDK4/6i even though 5 patients switched to a different CDK4/6i. 26.5% of patients had bone only disease and only 1 patient had brain metastasis at the time of CDK4/6i retri al. Across all patients in the cohort, the median number of prior therapy lines for metastatic disease before CDK4/6i retri al was 3, and 91% of patients in this cohort received CDK4/6i as the immediately preceding therapy before retri al. Of the CDK4/6is, palbociclib (82%) was overwhelmingly used in first-line therapy, while abemaciclib (47%), palbociclib (44%), and ribociclib (9%) were used for retri al.


In Cohort 2 (*n* = 48), all patients progressed through ET + CDK4/6i and underwent CDK4/6i retri al at some point in the future with the same original CDK4/6i but different ET agent. At the time of retri al, 4 patients (8.3%) had to stop treatment due to toxicity; 31.2% of patients had bone-only disease, while 10% had brain metastases. Median number of prior treatment lines by time of CDK4/6i retri al was 2. The primary CDK4/6i in this cohort was palbociclib, which was given to 94% of patients for both initial treatment and retri al. 85.4% of patients in this cohort underwent CDK4/6i retri al immediately after progression to the first CDK4/6i regimen.

Cohort 3 (*n* = 127) represented all patients who progressed through ET + CDK4/6i and subsequently underwent CDK4/6i retri al with a different CDK4/6i from their original combination therapy. At the time of retri al, 8 patients (6.3%) had to stop treatment due to toxicity; 18% of patients had bone only disease and 11% had brain metastasis. This cohort was overall more heavily pretreated than the other two, as the median number of prior treatment lines by time of retri al was 5, and only 35.4% of patients underwent CDK4/6i retri al as the immediately subsequent therapy line after progression on initial therapy. The overwhelming majority of patients in this cohort were initially treated with palbociclib (96%), with abemaciclib (81.9%) being the primary CDK4/6i of choice for retri al. SERDs (61.5%) were the most common endocrine partner at re-treatment. Separately, 26.5% of patients in this cohort were treated with abemaciclib monotherapy at retri al.

### Time to treatment failure with CDK4/6i retri al

Kaplan-Meier curves summarizing median time to treatment failure (TTF) of both initial CDK4/6i treatment and CDK4/6i retri al are organized per cohort in Fig. 2. Swimmer plots comparing individual TTF for both initial CDK4/6i treatment and CDK4/6i retri al side-by-side per patient are illustrated in Figs. 3–5. Median TTF for CDK4/6i retri al compared to initial CDK4/6i exposure in Cohort 1 was 10.1 months (95%CI, 4.8–16.9) vs 3.0 months (95%CI 2.8–6.3), in Cohort 2 was 4.3 months (95%CI 3.2–5.5) vs 10.0 months (95%CI 7.6–12.2), and in Cohort 3 was 4.7 months (95%CI 3.7–6.0) vs 10.0 months (95% 7.3–11.9). In Cohorts 2 and 3, most patients

**Fig. 1 | CDK4/6i retri al cohorts.** A flow/CONSORT diagram outlining how patients were divided into cohorts for data analysis is shown here. From our 195 total patients, patients were first separated depending upon why their first CDK4/6i regimen was discontinued. Patients who discontinued therapy due to toxicity were considered Cohort 1. The remaining patients (who had stopped initial CDK4/6i due to progression of disease (POD)) were further separated depending upon what type of combination regimen was chosen on retri al. Cohort 2 represented patients who kept the same CDK4/6i but changed endocrine therapy (ET) partner. Cohort 3 represented patients who were treated with a different CDK4/6i. Of note, 14 patients were treated with 3 separate lines of therapy containing a CDK4/6i and therefore were documented as separate treatment instances (treatments 1 and 2 vs treatments 2 and 3). These individual patients ended up in multiple cohorts to account for their multiple treatment instances.



**Table 1 | Baseline patient characteristics**

| Patient characteristics  | Cohort 1 (n 34)        |                      | Cohort 2 (n 48)        |                      | Cohort 3 (n 127)       |                      |
|--|------------------------|----------------------|------------------------|----------------------|------------------------|----------------------|
|  | First CDK4/6i exposure | CDK4/6i re-treatment | First CDK4/6i exposure | CDK4/6i re-treatment | First CDK4/6i exposure | CDK4/6i re-treatment |
| Prognostic markers   |                        |                      |                        |                      |                        |                      |
| Median age   | 61                     | 62                   | 56                     | 58                   | 61                     | 63                   |
| Bone only metastases <sup>a</sup>                                    | 9 (26%)                | 9 (26%)              | 18 (37.5%)             | 15 (31.2%)           | 40 (31.2%)             | 23 (18%)             |
| Sites of metastatic disease  |                        |                      |                        |                      |                        |                      |
| 1  | 18 (53%)               | 18 (53%)             | 22 (46%)               | 17 (35%)             | 49 (39.6%)             | 25 (19.7%)           |
| 2  | 6 (18%)                | 4 (12%)              | 11 (23%)               | 9 (19%)              | 35 (27.6%)             | 31 (24.4%)           |
| 3  | 6 (18%)                | 8 (24%)              | 10 (21%)               | 12 (25%)             | 20 (15.8%)             | 29 (22.9%)           |
| ≥4   | 4 (12%)                | 4 (12%)              | 5 (10%)                | 10 (21%)             | 23 (18.1%)             | 42 (33.1%)           |
| Brain metastasis   | 1 (3%)                 | 1 (3%)               | 3 (6%)                 | 5 (10%)              | 10 (7.9%)              | 14 (11%)             |
| Prior treatment details  |                        |                      |                        |                      |                        |                      |
| De novo metastatic disease   | 11 (32%)               |                      | 16 (33%)               |                      | 34 (27%)               |                      |
| Median closest endocrine therapy duration in months <sup>b</sup>     | 2.6 (1.3–3.4)          |                      | 8.5 (3.6–12.3)         |                      | 4.7 (2.4–9.1)          |                      |
| Median chemotherapy lines prior to retri <sup>b</sup>                | 0 (0–0)                |                      | 0 (0–1)                |                      | 1 (0–3)                |                      |
| Endocrine partner  |                        |                      |                        |                      |                        |                      |
| Aromatase inhibitor  | 22 (65%)               | 16 (47%)             | 44 (92%)               | 1 (2%)               | 68 (54%)               | 14 (11%)             |
| SERD   | 11 (32%)               | 15 (44%)             | 1 (2%)                 | 45 (94%)             | 51 (40%)               | 78 (61%)             |
| Tamoxifen  | 0                      | 0                    | 0                      | 1 (2%)               | 0                      | 1 (0.7%)             |
| No endocrine partner   | 1 (3%)                 | 3 (9%)               | 3 (6%)                 | 1 (2%) <sup>c</sup>  | 8 (6%) <sup>d</sup>    | 34 (27%)             |
| CDK4/6i  |                        |                      |                        |                      |                        |                      |
| Palbociclib  | 28 (82%)               | 15 (44%)             | 45 (94%)               | 45 (94%)             | 122 (96.1%)            | 4 (3.2%)             |
| Abemaciclib  | 4 (12%)                | 16 (47%)             | 3 (6%)                 | 3 (6%)               | 4 (3.2%)               | 104 (81.9%)          |
| Ribociclib   | 2 (6%)                 | 3 (9%)               | 0                      | 0                    | 1 (0.8%)               | 19 (15%)             |
| Treatment sequencing   |                        |                      |                        |                      |                        |                      |
| CDK4/6i retri <sup>b</sup> immediately after initial CDK4/6i failure | 31 (91%)               |                      | 41 (85.4%)             |                      | 45 (35.4%)             |                      |
| Median lines of therapy for metastatic disease <sup>b</sup>          | 1 (1–3)                | 3 (2–4)              | 1 (1–2)                | 2 (2–4)              | 2 (1–4)                | 5 (3–7)              |
| First line   | 19 (56%)               | 0                    | 29 (60%)               | 0                    | 43 (33.9%)             | 0                    |
| Second line  | 6 (18%)                | 16 (47%)             | 7 (15%)                | 28 (58%)             | 28 (22.1%)             | 17 (13.4%)           |
| Third line   | 1 (3%)                 | 7 (21%)              | 4 (8%)                 | 6 (13%)              | 18 (14.2%)             | 23 (18.1%)           |
| Fourth and beyond  | 8 (24%)                | 11 (32%)             | 8 (17%)                | 14 (29%)             | 38 (30%)               | 87 (68.5%)           |

Baseline clinical characteristics are summarized and separated by respective cohort.

<sup>a</sup>Patient with bone lesions and breast primary lesion and/or lymph node involvement were included as bone only as far as no presence of visceral disease.

<sup>b</sup>Median (Interquartile Range).

<sup>c</sup>One patient received bicalutamide as endocrine partner.


<sup>d</sup>Six patients received bicalutamide as endocrine partner.

stopped treatment with CDK4/6i due to disease progression; otherwise, only 8.3% of patients in Cohort 2 and 6.3% of patients in Cohort 3 stopped due to toxicity. To compare the duration of CDK4/6i retri<sup>b</sup> to that of initial therapy, we calculated a ratio (which we called the TTF2/TTF1 ratio) by dividing TTF of retri<sup>b</sup> by TTF of initial CDK4/6i. In Cohort 1, the median TTF2/TTF1 ratio was 1.6, with 60% of patients having a longer TTF on retri<sup>b</sup> compared to initial treatment (Fig. 3). Cohort 2 had a median TTF2/TTF1 ratio of 0.5, and only 29% of patients had a longer TTF2 with CDK4/6i retri<sup>b</sup> compared to initial treatment (Fig. 4). In this cohort, at the time of data censoring, 2 patients (4%) remained on treatment without further progression and 13 patients (27%) had a TTF2 longer than 9 months for CDK4/6i retri<sup>b</sup>. Cohort 3 had similar numbers to Cohort 2. Cohort 3 had a median TTF2/TTF1 ratio of 0.59, with 32% of patients having a longer CDK4/6i retri<sup>b</sup> duration than initial treatment (Fig. 5). At the time of data

censoring, 15 patients in Cohort 3 (11.8%) remained on treatment without further progression and 37 patients (29%) had a TTF2 longer than 9 months on CDK4/6i retri<sup>b</sup>.


**Best overall response**

Best overall response (BOR) to first exposure and retri<sup>b</sup> of CDK4/6i are summarized in Supplementary Table 1. In Cohort 1, where patients had not demonstrated progression on a CDK4/6i yet, 29% of the patients had radiographic response, 29% had stable disease (SD), 15% had progression of disease (PD), and 26% were non-evaluable (their treatment changed before first re-staging scan) in response to CDK4/6i retri<sup>b</sup>. In Cohort 2, where all patients had progressed on a preceding line of CDK4/6i, 15% had radiographic response, 25% had SD, and 48% had PD by time of first restaging scans for CDK4/6i



**Fig. 2 | Median Time to Treatment Failure (TTF).** Median TTF for both first CDK4/6i exposure and CDK4/6i retri are shown in the table above. Below each cohort is the respective survival curves for CDK4/6i retri. As noted before, median TTF for retri in Cohort 1 is substantially longer than median TTF for initial exposure. This relationship is inverted for Cohorts 2 and 3, again speaking to the biological difference between Cohort 1 and Cohorts 2 and 3.

**Fig. 3 | Cohort 1: Time to treatment failure at first CDK4/6i exposure vs. retri.** The two-headed swimmer plot for patients in Cohort 1 is shown here. For each patient, both the TTF for initial CDK4/6i exposure (blue, pointing leftward) and for CDK4/6i retri (pink, pointing rightward) are shown side-by-side. The TTFs for retri color-coded depending upon the treatment line for metastatic disease corresponding to CDK4/6i retri. TTF2 (2–3) = 2nd or 3rd line; TTF2 (4–5) = 4th or 5th line; TTF2 (>5) = 6th line and beyond.




retri, while 12% of patients were non-evaluable. In Cohort 3, again where all patients had previously progressed on a prior line involving CDK4/6i, 22% of patients had radiographic response, 24% had SD, and 41% had PD by time of first restaging scans for CDK4/6i retri, and 13% of patients were non-evaluable. All patients who had radiographic response were initially treated with palbociclib, and 82% of these patients were switched to abemaciclib for CDK4/6i retri, including 6 patients (21% of responders) who were treated with abemaciclib monotherapy.

**Univariate and multivariate analysis**


We conducted Cox regression for survival analysis to both compare TT1 to TTF2 and to determine variables associated with a higher TTF2. In Cohort

1, initial CDK4/6i exposure (TTF1) was significantly shorter than CDK4/6i retri (TTF2) (HR 0.40, 95%CI 0.24–0.70,  $p = 0.001$ ); in Cohort 2, TTF1 was not significantly different from TTF2 (HR 1.41, 95%CI 0.94–2.14,  $p = 0.09$ ); in Cohort 3, TTF1 was significantly longer than TTF2 (HR 1.44, 95%CI 1.11–1.87,  $p = 0.007$ ). For Cohort 2, none of the variables tested on univariate or multivariate Cox regression were significantly associated with a higher TTF2 (variables included: presence of bone-only disease, presence of brain metastases at treatment, treatment line of CDK4/6i retri, TTF of initial CDK4/6i treatment, and best response to initial CDK4/6i treatment by PRISMM criteria). For Cohort 3, using the same variables, univariate Cox regression found having bone-only metastases to be significantly associated with higher TTF2 (HR 0.57, 95%CI 0.31–0.83,  $p = 0.03$ ), while having brain metastases was associated with significantly lower TTF2 (HR

**Fig. 4 | Cohort 2: Time to treatment failure at first CDK4/6i exposure vs. retriail.** The two-headed swimmer plot for patients in Cohort 2 is shown here, using the same notation as Fig. 3. TTF2 (2–3) = 2nd or 3rd line; TTF2 (4–5) = 4th or 5th line; TTF2 (>5) = 6th line and beyond.



**Fig. 5 | Cohort 3: Time to treatment failure at first CDK4/6i exposure vs. retriail.** The two-headed swimmer plot for patients in Cohort 3 is shown here, using the same notation as Figs. 3 and 4. TTF2 (2–3) = 2nd or 3rd line; TTF2 (4–5) = 4th or 5th line; TTF2 (>5) = 6th line and beyond.



1.78, 95%CI 1.49–2.07,  $p = 0.048$ ). However, on multivariate Cox regression, these variables lost statistical significance, yielding no variables associated with higher TTF2 similar to Cohort 2; however, having bone-only disease trended towards significance for a higher TTF2 (HR0.60, 95%CI 0.35–1.02,  $p = 0.06$ ).

**Somatic tumor mutation profiling and associations with retriail benefit**

In an exploratory analysis, we compared the somatic tumor mutation profiles (based on hybrid-capture panel-based NGS using MSK-IMPACT)<sup>14</sup> of patients in Cohort 3 that had a TTF2 at CDK4/6i retriail shorter than

4 months (representing clinically resistant disease on par with the median PFS of the placebo arm in the PALOMA-3 trial) to those with a TTF2 at the time of retreatment longer than 9 months (representing clinically responsive disease similar to the median PFS of the treatment arm in the PALOMA-3 trial)<sup>15</sup>. From the 53 patients with a TTF2 < 4 months and the 34 patients with a TTF2 > 9 months, we were able to identify 50 patients where somatic mutation profiling was done prior to any CDK4/6i exposure, 22 patients with profiling done in between the two CDK4/6i regimens, and 15 patients with genomic data collected post-progression to CDK4/6i retreatment.

The genomic results for these 87 patients are presented in the Onco-print shown in Fig. 6. As expected, patients with a shorter TTF2 to CDK4/6i retreatment had a higher frequency of genomic changes previously described as potential resistance mechanisms to CDK4/6i, such as *TP53* mutations (43% in low TTF2 cohort vs 21% in high TTF2 cohort), *CDK4* amplifications (4% vs 0%), *RB1* loss, (5% vs 0%) and *FAT1* loss-of-function mutations (5% vs 0%)<sup>16</sup>. Notably, all patients with *RB1* mutations acquired them after initial CDK4/6i exposure and all presented with immediate PD with CDK4/6i retreatment. None of the patients with prolonged TTF2 to CDK4/6i re-treatment had loss-of-function mutations in *RB1* or *FAT1*, although two patients in this group did develop *FAT1* variants of unknown significance after initial CDK4/6i exposure. Both groups of patients with TTF2 < 4 months and >9 months had near equal prevalence of mutations commonly seen after combination ET + CDK4/6i therapy, such as *PIK3CA* and *ESR1* mutations.


### Discussion

In this single-center retrospective cohort study, we report our experience with CDK4/6i retreatment for the treatment of heavily pre-treated ER + MBC. Within our center, we identified three discrete cohorts to describe CDK4/6i retreatment as a treatment strategy for this disease, and we report the real-world implications of this treatment strategy despite prior exposure to and treatment failure of CDK4/6i based regimens.

Of the cohorts identified, it is unsurprising that Cohort 1, which contained patients who had to stop initial CDK4/6i due to toxicity as

opposed to poor efficacy, represents separate biology when compared to patients who had to stop initial CDK4/6i due to disease progression on therapy. First, Cohort 1 was the only cohort with a notably higher median TTF for CDK4/6i retreatment when compared to initial exposure. Further, the patients in Cohort 1 experienced both comparably higher rates of clinical response and treatment-limiting toxicity compared to patients that had disease progression on initial CDK4/6i exposure (20.6% discontinuation rate due to toxicity in Cohort 1 compared to 8.3% in Cohort 2 and 6.3% in Cohort 3). Overall, this suggests that CDK4/6i retreatment after initial treatment failure due to toxicity is viable and should be considered as a further line of therapy in this patient population, with the caveat that the risk of similar toxicity is nontrivial. Most of this cohort switched CDK4/6i, but some patients underwent retreatment with palbociclib again, though at a lower starting dose and in a later treatment line. Of the patients in Cohort 1 that had to stop CDK4/6i retreatment due to treatment toxicity, almost all (6/7 patients) had to stop retreatment therapy due to the same toxicity experienced with initial CDK4/6i even though they switched to a different CDK4/6i. These results suggest that there exists a subset of patients that are uniquely sensitive to toxicity from CDK4/6i's as a class and that switching individual agents may still not be enough to abrogate this toxicity.

Regarding efficacy of a CDK4/6i retreatment strategy post-progression, the three prospective trials mentioned above (PACE, PALMIRA, and MAINTAIN), have altogether still not provided conclusive evidence whether CDK4/6i inhibition adds any differential efficacy compared to next-line endocrine therapy alone, mainly due to conflicting results between the trials in question. In all three trials, most patients had previous exposure and progression on palbociclib, which is one argument to as why MAINTAIN, which changed both the endocrine therapy partner and the CDK4/6i in subsequent treatment lines, yielded a positive result. Further, while the three main CDK4/6i approved for ER+ MBC were initially considered equivalent based upon the comparable PFS data from the initial trials, longer-term follow-up showed differential OS benefit between the three agents, with abemaciclib and ribociclib showing comparable median OS's of 67.1



**Fig. 6 | Genomic alterations in patients with short and long TTF to CDK4/6i retreatment in Cohort 3.** Somatic tumor mutation profiles of patients in Cohort 3 that had good response (>9 months TTF) and poor response (<4 months TTF) for CDK4/6i retreatment. Each column represents an individual patient, organized first by BOR by PRISMM criteria then by timing of mutational profile sample (Before first CDK4/6i, In-Between initial exposure and retreatment, or After CDK4/6i retreatment). *RB1* and *FAT1* loss of

function mutations as well as *CDK4* amplifications were seen exclusively in patients with TTF < 4months. Two patients in the TTF > 9 months had *FAT1* mutations that were variants of unknown significance. Other classical ER + MBC resistance mutations, such as those in *TP53*, *PIK3CA*, and *ESR1* were fairly evenly distributed between the two subgroups.

months in MONARCH 3<sup>17</sup> and 63.9 months in MONALEESA-2<sup>18</sup>, respectively. Palbociclib originally showed a notably shorter OS of 53.9 months in PALOMA-2<sup>9</sup>, but the separate PARSIFAL-LONG trial reported a more comparable palbociclib OS of 65.4 months<sup>20</sup>. Since direct head-to-head data comparisons are not available, this OS discrepancy between studies has led to growing suspicion that the different CDK4/6is are not equivalent, with multicentric studies demonstrating key molecular differences and resistance patterns between the three agents<sup>21</sup>. These altogether raise the additional question of whether switching CDK4/6is upon retreatment provides additional clinical value.

Due to the retrospective nature of our study and lack of a comparator arm, our data unfortunately cannot clarify this question further, but it does help frame the trial results through a real-world lens and may add more context for the disparate trial results. Given that a small minority of patients in both Cohort 2 and 3 discontinued treatment due to toxicity, the median TTF2s for both Cohorts 2 (4.3 months) and 3 (4.7 months) roughly approximate PFS, which in turn also approximates in scale the median PFS's seen in these trials: PACE 4.6 months<sup>10</sup>, PALMIRA 4.2 months<sup>11</sup>, MAIN-TAIN 5.2 months<sup>12</sup>. The specific question of whether changing CDK4/6i on retreatment yields differential efficacy is of particular clinical interest; a separate multicenter retrospective analysis investigating 87 patients specifically treated with abemaciclib after progression on either palbociclib or ribociclib similarly showed a median PFS of 5.3 months for these patients and also suggested that abemaciclib remains a viable treatment strategy for CDK4/6i retreatment<sup>22</sup>. Our data from Cohort 3 corroborates these findings with a larger sample size, but both studies lacked direct comparator arms (our study includes Cohort 2 as the subgroup of patients who did not switch CDK4/6i, but our analysis was not powered for direct comparison of Cohort 2 and 3, and there were a number of clinical differences that may confound any PFS differences, notably that Cohort 3 was on the whole more heavily pre-treated but also had a greater proportion of patients with TTF2 > 9 months). Overall, we must take caution in comparing the data from our heterogeneous real-world population, which is distinct from the patients enrolled in the prospective trials mentioned above. Nevertheless, a number of large, randomized phase III trials are either fully enrolled or underway that are prospectively investigating abemaciclib after progression on a prior CDK4/6i with a number of different endocrine therapy partners, namely postMONARCH<sup>23</sup>, EMBER-3<sup>24</sup>, and ELAINE 3<sup>25</sup>. The results of these trials will hopefully provide more definitive data to guide clinical practice.

Our data does instead clearly demonstrate that this patient population is heterogeneous, and the clinical and genomic complexity of this group warrants patient assessment on an individualized basis regarding the appropriateness of CDK4/6i retreatment as a treatment strategy. Specifically, there was a sizable proportion of patients that derived significant benefit (TTF2 > 9 months) in both Cohort 2 (27.1%) and Cohort 3 (29.7%). While not significantly associated with longer TTF2 on multivariate analysis, both the presence of bone-only disease and the lack of brain metastases were significantly associated with longer response on univariate analysis and are both otherwise conventionally known to portend overall better outcomes. Genomically, *TP53* mutations were over-represented among patients with low TTF2, and well-known CDK4/6i resistance mutations such as *CDK4* amplification, *RBI* loss, and *FAT1* loss of function<sup>16</sup> were seen exclusively in patients with low TTF2. Specifically, all patients found to have *RBI* alterations were also noted to have immediate disease progression upon CDK4/6i retreatment. Interestingly, many of the patients with the longest duration of response in Cohort 3 were among the most heavily pre-treated. For these patients, there were no clear clinical or genomic features to distinguish this subset beyond the trends mentioned above. Due to the overall low number of cases, this was a descriptive analysis that could be validated in future randomized studies but does suggest that the presence of known resistance mutations to ET + CDK4/6i after initial therapy would predict poor response to a CDK4/6i retreatment, regardless of whether the same or a different CDK4/6i is used. Taken together, these clinical and genomic characteristics may be useful metrics in selecting patients more likely to benefit from CDK4/6i retreatment while also identifying those that would likely have poor response.

Our study has a number of limitations. Most notably, the retrospective nature limits our ability to make definitive conclusions, as does our lack of an endocrine therapy only comparator arm. However, despite this, our results from Cohort 3, where the CDK4/6i was changed but ET was not for most cases, suggest that CDK4/6i inhibition is biologically relevant to the treatment results and the effects seen are not simply from ET alone. This is further supported by our genomic results, which show differential enrichment of classical CDK4/6i resistance mutations in the subgroup of patients with lower TTF2 alongside relative parity of *ESR1* mutations in both the higher TTF2 and lower TTF2 subgroups; if treatment effect was driven primarily by ET, we would expect this mutation distribution to be reversed. Another limit of our study is also the age and breadth of the data collection period. While the broad data analysis period is an independent strength because it allows assessment of longer-term follow-up for a larger number of patients, it is also a weakness given the rapid pace at which standard of care changes and new options become available. As such, the population of our study is historically reflective of the contemporary practice patterns prior to the newer OS data that have since informed modern practice: the overwhelming majority of our patients were treated with palbociclib as first CDK4/6i since it was what was available at the time and were overall treated with CDK4/6i in later lines, with no patients being treated with CDK4/6i in the adjuvant setting. Another aspect of the data's age that may affect overall generalizability is that our study cohort therefore disproportionately selected for patients with long-standing ER+ MBC who were being treated in a time where the main treatment options were still successive lines of cytotoxic chemotherapies, and newer targeted agents (such as antibody-drug conjugates or newer kinase inhibitors) were not available. Further, our data cannot speak to the potential efficacy of newer generation cell cycle inhibitors, like CDK4 or CDK2 inhibitors, or their place in a retreatment strategy. Further study of these newer agents will be necessary to answer the questions above.

In summary, this single-center, retrospective study presents proof of feasibility and tolerability of CDK4/6i retreatment in a large cohort of patients with heavily pre-treated ER+ MBC. In line with prior published data, our data suggests that a subset of patients might benefit from CDK4/6i retreatment and that using a different CDK4/6i at time of retreatment may be beneficial. First, for patients who stopped a CDK4/6i due to toxicity, rotation to a different CDK4/6i or rechallenge with the same CDK4/6i in a later treatment line is both a viable and effective strategy, with favorable TTF and toxicity profiles for the majority of patients on CDK4/6i retreatment. For patients who have progression on a CDK4/6i, individualized assessment at both the clinical and molecular levels is necessary for selection of patients most likely to derive benefit from a retreatment strategy. Our data is concordant with conventional knowledge that patients with bone-only disease tend to benefit from CDK4/6i retreatment more compared to those that have visceral metastases, even though it only trended towards statistical significance in this respect. Alternatively, *TP53* mutations, *CDK4* amplifications, and *RBI* or *FAT1* loss of function mutations may be molecular biomarkers predictive of CDK4/6i retreatment failure. Further investigation of the clinical and genomic features of response and resistance to CDK4/6i inhibition is necessary to answer many of the remaining questions about this treatment strategy. Overall, several phase 3 trials are currently underway to answer these many questions, and we eagerly await their results to more definitively address them.

## Methods

### Patients

Eligible patients were 18 years of age or older, had biopsy-confirmed unresectable stage III or stage IV ER+ breast cancer, were treated at our institution, and received two or more lines of treatment for advanced disease, with at least two prior lines containing a CDK4/6i. Patients with initial ER + /HER2+ breast cancer were excluded unless their disease reverted to a HER2-negative state by the time of CDK4/6i exposure. The MSK Institutional Review Board on Human Subjects approved this study (IRB 12-245 Appendix C). The study was not associated with a clinical trial. Since only de-identified information was collected as part of this study, we were able to

obtain a waiver of consent from the MSK institutional review board. This study complied with all relevant ethical regulations regarding patient data, in line with ethical norms and standards in the Declaration of Helsinki.

### Study Design

We performed a single-center, retrospective analysis of patients treated between May 2014 to December 2020 with at least two separate treatment lines containing a CDK4/6i for advanced ER+ breast cancer. Patients were identified through the MSK Breast Cancer Translational Platform (MSK-BCTP)<sup>7</sup> and the MSK pharmacy system. Detailed review of electronic medical records (EMR) was done by two independent physicians. Efficacy outcomes such as BOR and TTF were extrapolated from the EMR. For each line of treatment in a patient's case: start date, end of treatment date, and reason for therapy discontinuation (toxicity, progression, death or other) were annotated, standardized, and stored in our REDCap (Research Electronic Data Capture) platform. Somatic tumor mutation profiling via targeted hybrid-capture based NGS (MSK-IMPACT)<sup>14</sup> was recorded for pre-treatment (before any CDK4/6i exposure), inter-treatment (after only one treatment line containing CDK4/6i), and post-treatment (after all treatment lines containing CDK4/6i) biopsies when available.

Efficacy outcomes were evaluated in 3 different patient cohorts. For the number of heavily pre-treated patients that had been exposed to CDK4/6i in 3 or more treatment lines by time of data analysis, we extracted data from their two most recent lines containing CDK4/6i, with the earlier line counting as their "initial" treatment and the later line counting as "retreatment" for the purposes of our analysis. We first divided all patients based upon whether their initial CDK4/6i-containing line of therapy was discontinued due to treatment toxicity or progression of disease (POD) (Fig. 1). Cohort 1 therefore represents all patients who had incomplete exposure to CDK4/6i therapy at some point due to toxicity but subsequently were treated with either the same or separate CDK4/6i in a later treatment line. Among the patients who had stopped initial CDK4/6i therapy due to POD, these patients were further divided based upon whether their subsequent treatment with CDK4/6i included the same or a different CDK4/6i. Cohort 2 therefore represents all patients with POD on initial CDK4/6i who were subsequently re-treated with the same CDK4/6i but now combined with a separate endocrine therapy partner. Cohort 3 represents all patients with POD on initial CDK4/6i who were instead treated with a different CDK4/6i with the same or different endocrine partner in a later line of treatment.

### Outcomes

The primary objective of this study was to evaluate TTF on CDK4/6i retreatment in the 3 different pre-specified cohorts. TTF was defined as the time in months from when a patient started CDK4/6i retreatment to discontinuation of CDK4/6i for any reason, including disease progression, treatment toxicity, or death. We did not choose PFS as our endpoint because PFS would not adequately characterize the potential toxicity of this treatment strategy, which is something directly relevant to clinical practice. As a secondary end point, we evaluated tumor response to CDK4/6i retreatment in each of the 3 cohorts. Tumor response was assessed based on clinician assessment of response and investigator imaging review, as per PRISMM criteria. Patients that stopped CDK4/6i treatment before a re-staging image or only had non-measurable lesions were classified as non-evaluable patients.

To better understand potential associations between certain clinical variables and response to CDK4/6i retreatment, we included the following variables in our analysis: presence of bone-only disease, presence of brain metastasis, number of disease sites, treatment line of CDK4/6i retreatment, time to progression on initial CDK4/6i treatment, and best response to initial CDK4/6i treatment by PRISMM criteria<sup>26</sup>. As part of exploratory analysis, we also conducted a detailed genomic description of patients with the most disparate clinical outcomes and compared the genomic profiles of those with short (less than 4 months) to prolonged (more than 9 months) TTF to assess for any potential trends. These time points were chosen as a rough comparison to the results of the PALOMA-3 trial, which investigated

palbociclib + fulvestrant vs. placebo + fulvestrant in patients with MBC and reported PFSs of 9.5 months in the treatment arm vs. 4.6 in the placebo arm<sup>15</sup>.

### Statistical analysis

TTF was estimated using Kaplan–Meier methods, and survival curves were compared using long-rank test. The association of risk factors with TTF was analyzed using Cox proportional hazards method. Associations between clinical variables and outcomes were assessed with both univariate (using non-parametric paired statistical tests) and multivariate (using logistic regression) analyses. All statistical analysis was performed using R Statistical Software.

### Data availability

Data are available upon reasonable request at the discretion of the corresponding authors. Access to datasets used in this study should be requested directly from the corresponding authors and will involve data access request forms via Memorial Sloan Kettering Cancer Center. Subject to the institutional review boards' ethical approval, unidentified data may be made available as a test subset. Data analysis methods have been described thoroughly in the Methods section so they can be independently replicated.

Received: 8 April 2024; Accepted: 22 September 2024;

Published online: 18 October 2024

### References

- Noone AMHN et al. Cancer Statistics Review, 1975-2018 - SEER Statistics. [https://seer.cancer.gov/archive/csr/1975\\_2018/](https://seer.cancer.gov/archive/csr/1975_2018/) (2018).
- Pan, H. et al. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. *N. Engl. J. Med.* **377**, 1836–1846 (2017).
- Goyal, R. K. et al. Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: a SEER-Medicare population-based study. *Cancer* **129**, 1051–1063 (2023).
- Im, S.-A. et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. *N. Engl. J. Med.* **381**, 307–316 (2019).
- Sledge, G. W. et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. *JAMA Oncol.* **6**, 116–124 (2020).
- Rozeboom, B., Dey, N. & De, P. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future. *Am. J. Cancer Res.* **9**, 2821 (2019).
- Razavi, P. et al. The genomic landscape of endocrine-resistant advanced breast cancers. *Cancer Cell* **34**, 427 (2018).
- Ma, J., Chan, J. J., Toh, C. H. & Yap, Y. S. Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer. *NPJ Breast Cancer* **9**, 1–16 (2023).
- Giordano, S. H. et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. *J. Clin. Oncol.* **36**, 2615 (2022).
- Mayer, E. L. et al. Abstract GS3-06: GS3-06 palbociclib after CDK4/6i and endocrine therapy (PACE): a randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastatic breast cancer. *Cancer Res.* **83**, GS3–GS06 (2023).
- Llombart-Cussac, A. et al. Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[+])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial. *J. Clin. Oncol.* **41**, 1001–1001 (2023).
- Kalinsky, K. et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth



- factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. *J. Clin. Oncol.* **41**, 4004–4013 (2023).
13. Mayer, E. L. et al. PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer. *J. Clin. Oncol.* <https://doi.org/10.1200/JCO.23.01940> (2024).
  14. Cheng, D. T. et al. Memorial Sloan Kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology. *J. Mol. Diagn.* **17**, 251 (2015).
  15. Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* **17**, 425–439 (2016).
  16. Li, Z. et al. Loss of the FAT1 tumor suppressor promotes resistance to CDK4/6 inhibitors via the Hippo pathway. *Cancer Cell* **34**, 893–905.e8 (2018).
  17. Goetz, M. P. et al. MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC). *Ann. Oncol.* **35**, 718–727 (2024).
  18. Hortobagyi, G. N. et al. Overall survival with ribociclib plus letrozole in advanced breast cancer. *N. Engl. J. Med.* **386**, 942–950 (2022).
  19. Finn, R. S. et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2-ABC): analyses from PALOMA-2. *J. Clin. Oncol.* **40**, LBA1003–LBA1003 (2022).
  20. Llombart-Cussac, A. et al. PARSIFAL-LONG: extended follow-up of hormone receptor-positive /HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study. In *San Antonio Breast Cancer Symposium* (San Antonio, TX, 2023).
  21. Hafner, M. et al. Multiomics profiling establishes the polypharmacology of FDA-approved CDK4/6 inhibitors and the potential for differential clinical activity. *Cell Chem. Biol.* **26**, 1067–1080.e8 (2019).
  22. Wander, S. A. et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. *J. Natl. Compr. Cancer Netw.* 1–8 <https://doi.org/10.6004/JNCCN.2020.7662>. (2021).
  23. Kalinsky, K. et al. postMONARCH: a phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. *J. Clin. Oncol.* **40**, TPS1117–TPS1117 (2022).
  24. Eli Lilly and Company. A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3). Identifier NCT04975308 (2023). Accessed 1/12/2024.
  25. Goetz, M. et al. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. In *San Antonio Breast Cancer Conference* (San Antonio, TX, 2023).
  26. Kehl, K. L. et al. Artificial intelligence-aided clinical annotation of a large multi-cancer genomic dataset. *Nat. Commun.* **12**, 1–9 (2021).
- ### Acknowledgements
- We thank Memorial Sloan Kettering's Breast Translational Research group for the technical and database support in data curation and extraction to assist in the creation and management of our dataset. We also thank the clinical staff, including our nurses, office coordinators, and clinic coordinators, who helped take care of the patients represented in this study. The authors acknowledge the Memorial Sloan Kettering Cancer Center support grant (P30 CA008748) for its support. This study received no other funding.
- ### Author contributions
- C.A., A.S., P.R., and K.J. developed the concept for this study. C.A. and A.S. developed the initial dataset, while N.M. curated and expanded the dataset for analysis. N.M., A.S., S.P., and Y.C. designed and performed the statistical analysis. C.A., A.S., and N.M. designed and created the associated figures. NM wrote the manuscript. All authors read and approved the final manuscript.
- ### Competing interests
- Larry Norton, MD is the Editor-in-Chief for *NPJ Breast*. Sarat Chandralapaty, MD PhD is an editor for *NPJ Breast*. The other authors declare they have no known competing financial interests or personal relationships that appeared to have influenced the work presented here.
- ### Additional information
- Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41523-024-00699-3>.
- Correspondence** and requests for materials should be addressed to Komal Jhaveri.
- Reprints and permissions information** is available at <http://www.nature.com/reprints>
- Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- ### Open Access
- This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.
- © The Author(s) 2024